Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its operations into 2026, beyond results from its Phase 1 clinical trials of SL-172154. This cash runway guidance is based on the Company’s current operational plans and excludes any additional capital that may be received, proceeds from business development transactions, and/or additional costs associated with clinical development activities that may be undertaken.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STTK:
- Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
- Shattuck Labs announces addition to Russell 2000, Russell 3000 Indexes
- Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
- Shattuck Labs price target lowered to $16 from $28 at H.C. Wainwright
- Trade Desk initiated, Best Buy upgraded: Wall Street’s top analyst calls
Questions or Comments about the article? Write to editor@tipranks.com